India tightens drug safety rules after global contamination scandals

India’s drug regulator has introduced stricter rules for monitoring drug safety and adverse reactions. The Central Drugs Standard Control Organisation (CDSCO) recently updated Schedule M, which governs manufacturing standards for pharmaceutical companies. These changes follow concerns over contaminated medicines linked to child deaths abroad and aim to strengthen oversight in the industry. The updated Schedule M now includes clearer pharmacovigilance requirements, ensuring companies track and report adverse drug reactions (ADRs). Every licence holder must establish a system to collect, process, and forward reports on safety issues related to their products. Regulatory officers from the CDSCO, State Licensing Authorities, and Union Territory administrations will check compliance during inspections.

The new rules align India’s Good Manufacturing Practices (GMP) more closely with global standards set by the World Health Organization (WHO). Health experts see this as a key move to improve post-marketing surveillance and hold manufacturers accountable. A strong pharmacovigilance system can help detect safety risks early, trigger recalls if needed, and prevent large-scale health crises. The CDSCO’s circular comes after reports of contaminated cough syrups containing toxic substances, which were linked to child fatalities in other countries. These incidents raised global concerns about pharmaceutical quality control and the need for better monitoring after drugs reach the market.

Pharmaceutical companies in India must now implement stronger systems to monitor drug safety. The updated regulations require timely reporting of adverse reactions and regular checks by authorities. These measures are designed to reduce risks, improve public health protections, and restore confidence in Indian-made medicines.